Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T22:19:08.216Z.
Calculation as of: 2026-10-06T22:19:08.216Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 97452f2638ad5d60f1716ef7360feea6a822b872a50cf44a9ba771f9e60b5836
PE RATIO
N/A
Market Cap
$10.19B
PE Ratio
1027.21
TTM Avg
232.01
3Y Avg
88.58
5Y Avg
62.84
Market Cap
$10.72B
PE Ratio
7.26
TTM Avg
8.55
3Y Avg
11.98
5Y Avg
12.10
Market Cap
$10.87B
PE Ratio
144.15
TTM Avg
51.36
3Y Avg
60.18
5Y Avg
194.40
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Twist Bioscience Corporation (TWST) | $10.40B | N/A | N/A | N/A | N/A |
| Globus Medical, Inc. (GMED)vs › | $10.31B | 19.65 | 23.15 | 68.05 | 56.59 |
| 10x Genomics, Inc. (TXG)vs › | $10.24B | N/A | N/A | N/A | N/A |
| Molina Healthcare, Inc. (MOH)vs › | $10.19B | 1027.21 | 232.01 | 88.58 | 62.84 |
| ImmunityBio, Inc. (IBRX)vs › | $10.15B | N/A | N/A | N/A | N/A |
| Align Technology, Inc. (ALGN)vs › | $10.13B | 24.56 | 29.33 | 36.97 | 43.63 |
| Universal Health Services, Inc. (UHS)vs › | $10.72B | 7.26 | 8.55 | 11.98 | 12.10 |
| The Ensign Group, Inc. (ENSG)vs › | $10.03B | 26.97 | 30.73 | 30.61 | 27.70 |
| BioMarin Pharmaceutical Inc. (BMRN)vs › | $10.87B | 144.15 | 51.36 | 60.18 | 194.40 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.93B | 44.71 | 34.03 | 32.06 | 21.08 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$166.97
Forward EPS (Est.)
$-1.38
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
